September 28, 2022

For nearly two decades, Buettner has been unriddling the secrets of those hotspots around the world where people live the longest, happiest lives. He will share his surprising new research on the profound impact diet has on longevity at the conference where longevity science will be a hot topic
MIAMI, Sept. 8, 2022 /PRNewswire-PRWeb/ — The Global Wellness Summit (GWS), the most prestigious conference on the $4.4 trillion business of wellness, today announced that Dan Buettner, who famously identified the Blue Zones–those five places around the world where people live significantly better, longer lives–will keynote at the conference being held in Tel Aviv, Israel from October 31 to November 3. Buettner is an explorer, a National Geographic Fellow, an award-winning journalist and producer, and the author of four runaway bestsellers. His new book, "Blue Zones American Kitchen," which uncovers the traditional roots of plant-forward cuisine in the US, will be released in December. A four-part documentary series on lessons from the Blue Zones will premiere in early 2023.
Since 2004, Buettner has been researching Blue Zone communities (in Sardinia, Italy; Okinawa, Japan; Nicoya, Costa Rica; Ikaria, Greece; and Loma Linda, California) to understand what keeps people thriving and healthy to age 100. His discovery: their longevity has nothing to do with self-discipline, or complex health and fitness regimes. Instead, it's these communities' holistic ecosystems that make the healthy choice the easy one: Residents are naturally "nudged" toward daily movement, a plant-based diet, strong social connections, and a sense of purpose.
New research on longevity diets: At the Summit, he will present his latest research on what the world's longest-lived people eat and the eye-opening impact that diet has on longevity. He will share surprising insights from his new "Blue Zones American Kitchen," which uncovers the regions and cultures that have shaped America's healthiest food landscapes. These include some of the most under-recognized plant-forward communities, from Hmong elders in Minnesota to Quakers in New England. Buettner will explore how a restoration of these specific, traditional healthy eating subcultures around the world could save us trillions of dollars a year in healthcare costs.
"Dan wowed delegates at the 2018 Summit and we're thrilled to have him share his latest research this year. His work on how total environment and culture are the lynchpins of longevity is increasingly changing the way the world thinks about health, wellness, prevention and aging. And it's also having a growing impact on public policy, wellness community design, and longevity science, all big topics at this year's conference," said Susie Ellis, GWS chair and CEO.
"The overwhelming finding from my years of research is that the path to a long and happy life is not about changing your habits, it's about changing your surroundings. Leaders in public policy, architecture and design, wellness real estate, and hospitality that will gather at the conference now have the greatest opportunity to architect communities and environments so that people's daily decisions are naturally the healthy ones," said Buettner. "I'm so happy to return to the Summit. I've given thousands of speeches in the last decade and I rarely return to a conference, but I had more fun at the GWS in Italy than I've had at any conference ever."
Longevity Science–A Key Summit Topic: The longevity science market is forecast to reach $600 billion by 2025, and new approaches that can bring unprecedented increases to the quality and length of human lifespans ("healthspans") have become one of the buzzed-about topics in wellness and medicine. It will be a key focus at this year's GWS, where Buettner will join medical experts such as Shai Efrati, MD, of Tel Aviv University, who is pioneering medical hyperbaric oxygen treatments shown to reverse the biology of aging, and Tzipora Strauss, MD, who is co-leading a new longevity medicine research center at Israel's Sheba University.
More about Buettner:
Buettner's books, "The Blue Zones: Lessons for Living Longer from the People Who've Lived the Longest," "Thrive: Finding Happiness the Blue Zones Way," "The Blue Zones of Happiness," and "The Blue Zones Solution: Eating and Living Like the World's Healthiest People," were all global bestsellers. He regularly appears on major news programs, including the Today Show, NBC Nightly News and the BBC, and has keynoted at some of the most important global conferences, including the World Economic Forum and Bill Clinton's Health Matters Initiative. He also holds three Guinness World Records in distance cycling.
Registration for the 2022 Summit is open.
About the Global Wellness Summit —The Global Wellness Summit is the premier organization that brings together leaders and visionaries to positively shape the future of the $4.4 trillion global wellness economy. Its future-focused conference is held at a different global location each year and has traveled to the United States, Switzerland, Turkey, Bali, India, Morocco, Mexico, Austria, Italy and Singapore. GWS also hosts other virtual and in-person gatherings, including Wellness Master Classes, Wellness Sector Spotlights, Investor "Reverse Pitch" events and Global Wellness Symposiums. The organization's annual Global Wellness Trends Report offers expert-based predictions on the future of wellness. The 2022 Summit will be held in Tel Aviv, Israel from October 31 to November 3.
Media Contact
Beth McGroarty, Global Wellness Summit, +1 213-300-0107, beth.mcgroarty@globalwellnesssummit.com
SOURCE Global Wellness Summit
New data from the first of a new type of cancer drug suggest its benefits and limitations, while leaving room for other candidates seeking to enter the lucrative market. Amgen lung-cancer pill Lumakras beat out a common chemotherapy in a late-stage study, helping patients survive without their tumors getting worse, though it failed to prove that it reduced overall deaths, the company said. The Food and Drug Administration conditionally approved Lumakras last year based on encouraging early-stage study data but required Amgen to conduct a confirmatory study, which the company reported Sunday.
Clovis Oncology Inc (NASDAQ: CLVS) announced results from a subgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca versus placebo in advanced ovarian cancer. The data showed that Rubraca as a first-line maintenance treatment improved progression-free survival (PFS) versus placebo across disease risk subgroups, including surgical outcome, response to first-line chemotherapy, and additional analyses in other subgroups. Patients who received Rubraca as maintenance therapy showed benefit
Cancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. On Sunday, Clovis reported that Rubraca tested very well as a monotherapy for ovarian cancer in the initial part of a phase 3 trial. All told, 538 women suffering from high-grade ovarian, fallopian tube, or primary peritoneal cancer took part in the trial.
Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.
Good news from the Food and Drug Administration (FDA) can send biotech stocks into the stratosphere. Patrick Bafuma (Mirati Therapeutics): One company that has to be champing at the bit to get FDA approval is Mirati Therapeutics, with its lead drug adagrasib.
Weight-loss and nutrition companies have lost half or more of their value in the past year despite expectations of a postpandemic boom.
By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update Phase 2 Trial of TNX-102 SL Initiated in Long COVID On August 22, 2022, Tonix (NASDAQ:TNXP) announced the initiation of the PREVAIL Phase 2 clinical trial of TNX-102 SL in patients with Long COVID ( NCT05472090 ), a heterogeneous condition that involves nociplastic pain following infection with and recovery from
FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.
The biotech sector, like most sections of the market, took a sound beating in the year’s first half. Recently, however, the segment’s performance has improved, and that has helped the NASDAQ Biotechnology Index (NBI) pull ahead of the NASDAQ (Up 13% over the past 3 months vs. the NASDAQ’s 3%). The Oppenheimer biotech team thinks there’s a simple explanation for this: “We believe that much of the recent outperformance has been driven by SMID caps, of which many have risen admirably in the past fe
Long-term care in residential facilities like nursing homes is a financial challenge for many. When dealing with a loved one who is disabled, elderly or ill, families often try every other kind of long-term care facility first. Because nursing homes … Continue reading → The post Nursing Home Costs: How You Can Cover Them appeared first on SmartAsset Blog.
Late Friday, Bristol Myers Squibb (ticker: BMY) announced that the Food and Drug Administration had approved its oral plaque psoriasis treatment deucravacitinib, which will be marketed under the name Sotyktu. More surprising than the approval was the FDA’s decision not to require a so-called “black-boxed warning” on the drug’s label, which the agency uses when a drug carries significant safety risks. Investors had been concerned that similarities between TYK2 inhibitors and another class of drugs, known as Janus kinase inhibitors, which have been the subject of significant FDA safety concerns, would lead the agency to put a black box on Sotyktu.
An analyst had a fresh new take on the company's prospects, and it wasn't all that positive.
The things to remember about dementia are that it is absolutely horrible for you and everyone around you; it’s a high probability; and when it comes to fighting it or avoiding it you are pretty much on your own. Alzheimer’s disease and related dementias are currently killing 6.5 million people in the United States and devastating the lives of many times that when you count the patients’ friends and family. The National Institutes of Health reckons this number is likely to double in the next four decades.
"We believe Sotyktu is a breakthrough in the treatment of patients suffering from moderate-to-severe plaque psoriasis," said Bristol Myers' chief medical officer Samit Hirawat.
Hundreds of clinics specializing in ketamine treatment for depression and other mood disorders have popped up in the U.S. in recent years. WSJ visits one clinic, Nushama, to learn why some entrepreneurs are betting that demand for ketamine will continue to rise. Photo illustration: Laura Kammermann/WSJ
The 35-year-old actress and activist discusses her thoughts on abortion rights.
Bristol Myers (BMY) secures an FDA nod for Sotyktu to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end
The StoneSprings Hospital Center wants to add a second medical office building in southeastern Loudoun County, near South Riding. The new 80,000-square-foot structure would go up on what’s currently a surface parking lot next to the hospital, which is owned by Nashville, Tennessee-based HCA Healthcare Inc. (NYSE: HCA), at 24440 Stone Springs Blvd., just off U.S. Route 50. The hospital already has a roughly 61,000-square-foot office building, constructed in 2016, immediately to its west.
U.S. known cases of COVID are continuing to ease and now stand at their lowest level since early May, although the true tally is likely higher given how many people are testing at home, where the data are not being collected.

source

Leave a Reply